Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Shroom family member 1 (SHROOM1) is a cytoskeletal regulatory protein expressed in a variety of human tissues including the brain, heart, skeletal muscle, colon, small intestine, kidney, placenta, and lung, as well as in melanomas. It is a component of the Shroom protein family, which is distinguished by conserved actin-binding motifs and an ability to interact with Rho kinase (Rock) to spatially assemble contractile actomyosin networks, underlying the regulation of cell shape and tissue architecture during development. SHROOM1 is localized to the cytoplasm and apical plasma membrane of sodium-transporting epithelial cells, where it participates in cell shape modulation. Its hypermethylation has been implicated in the pathology of osteoarthritis, and recent evidence in genome editing highlights SHROOM1 as a suppressor of homology-directed repair, suggesting potential relevance to therapeutic gene editing strategies. No approved drugs or small molecules directly target SHROOM1, and it is not currently considered a classical therapeutic target such as a receptor, enzyme, or transporter.
Not applicable. No established drugs directly target SHROOM1.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Shroom family member 1 (SHROOM1).